Translating immunology into new therapies for Inflammatory Bowel Disease by Dr. Fiona Powrie

TL;DR

Dr Fiona Poweri discusses the role of the microbiome-host immune system interaction in inflammatory bowel disease and the potential for new therapies.

Transcript

hey welcome everybody to a new global immuno talk i'm carla roethlin and i'm here today with one of our co-organizers dr enrique vega fernandez i would just like to remind you that next week we'll have dr pipa marak so we look forward to connecting with you again next week and now i will let enrique introduce our fabulous speaker today dr fiona pow... Read More

Key Insights

• 🏫 Fiona Poweri is a well-known and highly respected immunologist, currently serving as the Director of the Kennedy Institute of Rheumatology at the University of Oxford. She has made significant contributions to the understanding of the relationship between the microbiome and the host immune system, particularly in inflammatory bowel disease and other diseases such as arthritis and cancer.
• 🔬 Fiona's research has revealed the important role of the IL-23 Th17 axis in driving colorectal cancer. She has also identified cytokines such as IL-10 as biomarkers and therapeutic targets in resistant inflammatory bowel disease.
• 🌍 Fiona's work is highly influential and has been published in top-ranked journals, earning her numerous accolades and awards. She was awarded the Louis-Jeantet Prize for Medicine in 2012 and was elected as an international member of the National Academy of Sciences in 2020.
• 🧪 Fiona emphasizes the importance of a career in research in immunology, encouraging young scientists to believe in themselves, follow their ideas, and be persistent in pursuing opportunities. She highlights the impact that immunology research can have on improving health and society.
• 🎙️ Fiona's talk focuses on translating immunology into new therapies for inflammatory bowel disease, particularly in the context of mucosal immunology in the gut. She discusses the importance of the gut microbiome and its interactions with the host immune system, as well as the breakdown of these relationships in disease.
• 🔑 Fiona's work also covers the identification of distinct pathotypes in inflammatory bowel disease associated with treatment non-response. These pathotypes involve an activated neutrophil-stromal cell axis and inflammatory fibroblasts producing neutrophil-attracting chemokines. IL-1 is an important upstream driver in this process.
• ⚡️ There is potential for individualized targeting of different pathotypes in inflammatory bowel disease to improve treatment outcomes. Understanding the specific cellular interactions and tissue niches involved in each pathotype can guide the development of targeted therapies.
• 🌟 Fiona's research highlights the complexity of inflammatory disease, involving not only immune cells but also other cell types such as fibroblasts and mesenchymal cells. This underscores the importance of comprehensive translational immunology research in understanding and treating these diseases.

Questions & Answers

Q: What is the significance of the microbiome-host immune system interaction in inflammatory bowel disease?

The microbiome-host immune system interaction plays a crucial role in inflammatory bowel disease. Disruptions in this interaction can lead to disease progression and inflammation in the gut. Understanding these interactions can help develop new therapies for the disease.

Q: How do regulatory T cells contribute to inflammatory bowel disease?

Regulatory T cells play a vital role in maintaining immune homeostasis in the gut. They help regulate the inflammatory response and prevent excessive immune activation. Deficiencies or dysregulation in regulatory T cells can lead to chronic inflammation and contribute to the development of inflammatory bowel disease.

Q: What are the potential therapeutic targets for inflammatory bowel disease?

Interleukin-23 and oncostatin M have been identified as potential therapeutic targets for inflammatory bowel disease. These cytokines play a role in driving disease progression and have been associated with treatment non-response. Targeting these cytokines may help improve treatment outcomes for therapy-resistant patients.

Q: How do fibroblasts and neutrophils contribute to disease progression in inflammatory bowel disease?

Fibroblasts and neutrophils play a role in tissue remodeling and pathology in inflammatory bowel disease. Activated fibroblasts produce chemokines that attract neutrophils to sites of inflammation, leading to tissue damage and ulceration. Targeting the interaction between fibroblasts and neutrophils may offer new therapeutic strategies for treatment-resistant inflammatory bowel disease.

Summary & Key Takeaways

• Dr. Fiona Poweri discusses the importance of the microbiome-host immune system interaction in inflammatory bowel disease.

• She shares her research on the role of regulatory T cells and cytokines, such as interleukin-23 and oncostatin M, in driving disease progression.

• The study also explores the cellular landscape in therapy-resistant inflammatory bowel disease, highlighting the activation of fibroblasts and the accumulation of neutrophils as key factors.